Drug-eluting stents (DES), which maintain the mechanical advantages of bare-metal stents (BMS) and additionally deliver an anti-restenotic pharmacological therapy locally to the arterial wall, have been shown to reduce the neointimal hyperplasia that occurs after stent implantation, resulting in reduced rates of restenosis and the need for repeat revascularization procedures (1, 2) . Although the use of DES has been demonstrated to be efficacious and safe in both randomized and observational comparisons with BMS (3, 4) , late adverse events with significant clinical consequences have been observed after the use of DES, including stent thrombosis (ST), myocardial infarction (MI), and death (5, 6) . In addition to these late safety events, observations of late restenotic events occurring beyond 1 year after DES implantation have raised concerns of an attrition of DES efficacy over time (7) . Newer DES, incorporating more deliverable and biocompatible stent and polymer platforms, have been designed to mitigate the adverse vascular responses to DES with the goal of improving clinical outcomes over predecessor stents. Although most approval studies of newer DES platforms were designed to evaluate device performance at 1 year, overall concerns with regard to long-term stent performance have increased the importance of rigorous longterm follow-up within existing clinical trials of DES.
The ENDEAVOR IV trial (A Randomized, Controlled Trial of the Medtronic Endeavor Drug [ABT-578] Eluting Coronary Stent System Versus the Taxus Paclitaxel-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions) was a pivotal U.S. Food and Drug Administration-mandated multicenter randomized clinical trial comparing the use of the Endeavor zotarolimus-eluting stent (E-ZES) (Medtronic, Santa Rosa, California) with the Taxus Express paclitaxeleluting stent (PES) (Boston Scientific, Natick, Massachusetts) in single de novo coronary lesions. This trial demonstrated similar clinical outcomes with E-ZES and PES at 1 year, despite increased angiographic late loss with E-ZES (8) . We report the final 5-year results of this comparison between E-ZES and PES, specifically examining the performance of both devices relative to late efficacy and safety.
Methods
Study design and patient population. Details of the ENDEAVOR IV trial design, patient eligibility, endpoints, procedures, and outcomes through 3 years have been previously published (8 -10) . The ENDEAVOR IV trial was a randomized, prospective, single-blind, multicenter clinical trial designed to compare clinical outcomes to 5 years between patients undergoing percutaneous coronary intervention with E-ZES or PES. Eligible patients had a single de novo native coronary lesion with a reference vessel diameter between 2.5 and 3.5 mm, a lesion length Յ27 mm, and a diameter stenosis (DS) Ն50% and Ͻ100% by visual estimation. Exclusion criteria included recent acute MI, recent stroke or transient ischemic attack, left ventricular ejection fraction Ͻ30%, and previous percutaneous cardiovascular intervention within the past 9 months or planned within 30 days. The trial was approved by the institutional review board of each site, and all patients signed written informed consent before randomization and treatment. Procedures, follow-up, and endpoints. After 1:1 randomization to E-ZES or PES, all patients were prescribed dual antiplatelet therapy (DAPT) (aspirin 325 mg daily and clopidogrel 300 mg loading dose then 75 mg daily), beginning 24 h before stent placement and continuing for at least 6 months, with aspirin continued indefinitely and clopidogrel at operator discretion after 6 months. Clinical follow-up was performed at 30 days; 6, 9, and 12 months; and annually thereafter through 5 years. A subset of patients underwent angiographic follow-up at 8 months (8) .
The primary 9-month endpoint was target vessel failure (TVF), a composite of cardiac death, target vessel MI, and clinically driven target vessel revascularization (TVR). The occurrence of TVF as well as other secondary clinical endpoints, including major adverse cardiac events (MACE) and its individual components (death, target vessel MI, or clinically driven target lesion revascularization [TLR] ) and stent thrombosis (ST), were adjudicated through 5 years as previously defined (8, 9) . Temporal categories of ST (early, late, and very late) were defined according to the Academic Research Consortium (ARC) (11 Kirtane et al. 5-Year Follow-Up From the ENDEAVOR IV Trial research organization, was responsible for data management and analysis. All primary and secondary endpoints were adjudicated by an independent Clinical Events Committee blinded to stent randomization, and an independent data safety monitoring board reviewed clinical safety data, including all stent thrombosis events. Statistical analysis. The trial was designed to test the noninferiority of E-ZES compared with PES with respect to the primary endpoint of TVR at 9 months. Annual follow-up of clinical endpoints was pre-specified to 5 years; landmark analyses were performed with randomized cohorts of patients who were free of events at 1 year. Data were analyzed on an intention-to-treat basis. Categorical variables were compared with chi-square or Fisher exact tests, and continuous variables-expressed as mean Ϯ SD-were compared with the Student t test. Kaplan-Meier estimates were used to display cumulative incidence data with between group comparisons by the log-rank test. Cox proportional hazards regression was used to estimate hazard ratios (HRs) and their 95% confidence intervals (CIs). All statistical analysis was completed with SAS software (version 8.2 or higher, SAS Institute, Cary, North Carolina).
Results
A total of 1,548 patients were enrolled and randomized to E-ZES or PES at 80 sites across the United States (Fig. 1) . At 5 years, clinical follow-up was available for 722 patients (93.4%) in the E-ZES group and 718 patients (92.6%) in the PES group. Baseline patient, procedural, and angiographic characteristics were similar among the 2 randomized groups. The mean patient age was 64 years, 68% of enrolled patients were male, and 31% of patients had diabetes mellitus (Table 1) . Approximately two-thirds of the patients had type B2/C lesions with mean reference vessel diameters of 2.7 mm and lesion lengths of 13.4 mm (E-ZES) and 13.8 mm (PES). Clinical outcomes. At 5 years, the rate of TVR (12.7% for E-ZES vs. 15% for PES, p ϭ 0.22) was similar among both randomized groups (Table 2 , top), with similar rates of TLR (7.8% vs. 8.4%, p ϭ 0.70) and a trend toward a lower rate of nontarget lesion TVR with E-ZES compared with PES (6.8% vs. 9.5%, p ϭ 0.067). The overall rate of composite TVF at 5 years similarly trended lower for E-ZES compared with PES (17.3% vs. 21.3%, p ϭ 0.061).
With regard to safety endpoints at 5 years, there were similar rates of death (and cardiac death) among the 2 study groups ( Table 2 , top). However, there were significantly fewer target vessel MIs at 5 years in the E-ZES group compared with the PES group (2.6% vs. 6%, p ϭ 0.002), with an absolute difference of 3.4%. As a result, composite cardiac death/target vessel MI was lower with E-ZES compared with PES through 5 years (6.4% vs. 9.2%, p ϭ 0.049). Among the target vessel MI events within the study, most were non-Q-wave MIs with a more than 2-fold greater rate of these events occurring in the PES study arm (15 events with E-ZES vs. 38 with PES, p ϭ 0.002). The incidence of Q-wave target vessel MIs was low and similar in both study arms (4 with E-ZES vs. 5 with PES). Overall, rates of ST were no different between the 2 study arms, with 10 (1.4%) ARC definite/probable ST events in E-ZEStreated patients and 14 (1.9%) ST events in PES-treated patients (Fig. 3A, Table 3 ). Values are mean Ϯ SD (N) or % (n/N).
CCS ϭ Canadian Cardiovascular Society; E-ZES ϭ Endeavor zotarolimus-eluting stent (Medtronic, Minneapolis, Minnesota); PES ϭ Taxus paclitaxeleluting stent (Boston Scientific, Natick, Massachusetts); MI ϭ myocardial infarction; PCI ϭ percutaneous coronary intervention.
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Landmark analyses. Among patients free of events at 1 year, the rates of late TLR, nontarget lesion TVR, and overall TVR were nonsignificantly different between E-ZES and PES (Table 2, bottom) . Similarly, overall mortality and cardiac death were no different between both study groups. However, there was a significantly lower rate of late target vessel MI with E-ZES (9 events, 1.3%) compared with PES (24 events, 3.5%) (HR: 2.7 for PES vs. E-ZES, 95% CI: 1.3 to 5.8, p ϭ 0.008) (Fig. 2) . Notably, 31 of the 33 MI events were spontaneous rather than associated with repeat revascularization procedures. Of the 33 late MI events, 30 were non-Q-wave MIs (1 Q-wave MI with E-ZES, and 2 with PES). The rate of ARC definite/probable very late stent thrombosis (VLST) was significantly lower with E-ZES (3 events, 0.4%) compared with PES (13 events, 1.8%), with a more than 4-fold higher incidence of VLST observed with PES (HR: 4.36, 95% CI: 1.24 to 15.30, p ϭ 0.012) (Fig. 3B) . Notably, this reduction was observed despite a greater proportion of patients continuing DAPT in the PES arm at 5 years (41.8% vs. 47.9%, p ϭ 0.03) (Fig. 4) .
Discussion
The ENDEAVOR IV trial was a large-scale pivotal randomized trial comparing the performance of E-ZES with PES in patients with single de novo coronary artery lesions. The primary results of this analysis reporting the final 5-year follow-up of patients treated within this trial are the following: 1) E-ZES and PES were associated with similar efficacy over the entire follow-up period, with no significant differences observed in the incidence of TLR or TVR; 2) E-ZES was associated with a significantly lower rate of target vessel MI, including MI occurring between years 1 to 5 (most of which were spontaneous); and 3) although overall rates of ST were nonsignificantly different between E-ZES and PES, the incidence of VLST was significantly lower with E-ZES compared with PES, despite less frequent adherence to DAPT at 5 years.
The E-ZES platform uses a cobalt alloy modular stent design to rapidly deliver the antiproliferative rapamycin analogue zotarolimus from a thin layer of biocompatible phosphorylcholine polymer. Phosphorylcholine is a naturally occurring phospholipid found in the membrane of red blood cells and is resistant to platelet adhesion (12) . The potencies of zotarolimus and other rapamycin analogues are roughly comparable; however, the release rate of zotarolimus from E-ZES (approximately 90% within 7 days, 100% within 30 days) is significantly faster than with other contemporary DES, including PES, which elutes paclitaxel over months. Therefore, although E-ZES offers potential advantages over existing DES platforms through a shorter elution time from a biocompatible polymer, the short (burst) elution with E-ZES likely also results in the greater angiographic late loss observed with this stent, as demonstrated in several previous randomized trials, including the primary analysis of the ENDEAVOR IV trial. Of note, the E-ZES studied in the ENDEAVOR IV trial should be differentiated from the currentgeneration Resolute-ZES, a DES that-while sharing the same eluted agent zotarolimus-is characterized by an updated stent/delivery system as well as a polymer modification designed to prolong elution time and reduce late loss (13) .
Despite the greater late loss observed in this and other trials of E-ZES (14), the overall rates of restenosis-related endpoints were similarly low and no different with both E-ZES and PES in this trial. The low rate of protocolmandated routine angiographic follow-up in this study, combined with a lower-risk patient population, might partially explain these results. In contrast to an analysis of the ENDEAVOR III trial in which the incidence of late TLR occurring from years 1 to 5 was only 1.3% with E-ZES-with most TLR events occurring within the first year of follow-up (14)-in the present trial, the rate of TLR occurring between years 1 to 5 was 4.1%. Differences in the Values are n (%).
Abbreviations as in Table 1 .
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performance of E-ZES between these 2 trials are likely explained by the low rate of routine angiographic follow-up in the present trial, which likely avoided "clustering" of TLR events at the time of the follow-up angiogram (before 1 year). In the ENDEAVOR IV trial, we did not observe an appreciable difference in late restenosis events with E-ZES compared with PES, although the incidence of TLR occurring beyond 1 year was numerically greater among PEStreated patients, reversing the finding of numerically lower TLR at 1 year. Because the time frame upon which DES evaluations are based has in the past several years shifted away from short-term results to longer-term outcomes, the potential for increased biocompatibility with E-ZES has been linked to improvements in safety outcomes, particularly those assessed beyond 1 year. Both pre-clinical and in vivo testing D) during the first year and between 1 and 5 years after stent implantation for each study arm. CI ϭ confidence interval; E-ZES ϭ endeavor zotarolimus-eluting stent; HR ϭ hazard ratio; PES ϭ paclitaxel-eluting stent.
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have demonstrated more rapid and complete endothelialization of stent struts with E-ZES (15, 16) , with additional improvements in surrogate safety endpoints assessed by intravascular ultrasound, optical coherence tomography, and vasomotor testing (17) (18) (19) (20) . These surrogate endpoint-based observations have also translated into favorable safety outcomes in clinical trials of E-ZES. In a pooled analysis of 2,132 patients enrolled in 6 trials of E-ZES, the overall rates of cardiac death, MI, and stent thrombosis were low and no different from that of BMS, albeit in a nonrandomized comparison (21) . In the ENDEAVOR III randomized trial comparing E-ZES with the Cypher sirolimuseluting stent (Cordis, Warren, New Jersey), despite higher late loss, E-ZES was associated with lower rates of TVF, composite cardiac death/MI, and overall mortality at 5 years (14).
The present study findings extend these prior observations with regard to the late safety of E-ZES. The reduction in target vessel MI observed with E-ZES within this trial is notable, with an absolute difference in MI of 3.4%, equating to a number needed to treat 29 patients to prevent 1 MI event. Significant reductions were observed in both overall MI as well as late MI (occurring beyond 1 year). Prior analyses of this trial have demonstrated reductions in periprocedural MI with E-ZES compared with PES, with a greater degree of side-branch compromise observed after PES implantation (22) . The finding of a 2.7-fold reduction in late target vessel MI, the vast majority of which were spontaneous (rather than periprocedural), adds to this early benefit and is very reassuring with regard to the late safety of E-ZES. The observed reduction in late MI seemed to be partially (but not wholly) driven by a reduction in VLST The cumulative incidence of Academic Research Consortium (ARC) definite and probable stent thrombosis through 5 years (A) and the cumulative incidence of ARC definite and probable stent thrombosis from 1 to 5 years (B). Abbreviations as in Figure 2 .
with E-ZES compared with PES. Although DES have been unquestionably shown to be efficacious in reducing restenosis and repeat revascularization, the occurrence of late events, such as VLST is perhaps the greatest limitation of DES technology. Thus, even small improvements in the late safety profile of DES shift the risk/benefit balance in favor of DES (23) and in fact render this technology a more attractive option for patients. Therefore, the observation of these reductions in adverse late safety events with E-ZES is an important one and consistent with other observations with other newer and more biocompatible DES platforms compared with predecessor stents (24, 25) .
These reductions in late events were observed in the setting of a generally low overall adherence to prolonged DAPT (particularly over the longer-term follow-up period) and notably with a lower rate of adherence in the E-ZES compared with the PES study arm. At present, there are limited data with regard to the overall utility of continued DAPT for patients treated with DES (26, 27) . Without an effective therapy to prevent late events from occurring, the evaluation and use of incrementally safer DES platforms is even more paramount. In this regard, the findings of this trial support the further study of E-ZES as a potentially safer DES platform compared with PES. Study limitations. The lesion and patient inclusion criteria for the ENDEAVOR IV trial were somewhat restrictive, as with most pivotal early stage randomized clinical trials used for Food and Drug Administration approval of a DES in the United States. Thus, the reported findings can only be applied to single simple-to-medium complexity lesions in patients who were, by and large, stable. The knowledge of stent type by patients and physicians at the completion of 1-year follow-up might have influenced differential clinical decision-making downstream of randomization. Finally, the ENDEAVOR IV trial was powered to test the noninferiority of ZES versus PES for TVF and in-segment late loss; as such, the significance of other endpoint comparisons should be considered exploratory and should be viewed with caution, particularly because they are not adjusted for multiple comparisons. Definitive conclusions with regard to safety endpoints, including death, MI, and ST (especially for the low-frequency endpoint of VLST), require an adequately powered clinical trial with much greater sample size than the present comparison between E-ZES and PES. In this regard, the large randomized PROTECT (Patient Related OuTcomes with Endeavor versus Cypher stenting Trial), conducted in 8,791 patients with native coronary artery lesions, demonstrated similar rates of definite/probable ST with the 2 stent types but lower rates of definite ST with E-ZES compared with sirolimus-eluting stent at 3 years (28) .
An additional limitation to these data is that the relevance to current patient care might be somewhat limited, given that this trial compared the use of 2 stents that have since been updated and have very limited current use relative to more modern-generation DES platforms. However, the importance of rigorous collection and presentation of longterm data on coronary devices cannot be overstated, because these data help to provide assurance of the absence of deleterious late safety signals signifying potential harm to patients.
Conclusions
These data demonstrate the durable efficacy and safety of E-ZES in a randomized comparison with PES for the treatment of de novo coronary artery lesions. Significant improvements in late safety outcomes (most notably in target vessel MI and VLST) were observed with E-ZES but should be considered hypothesis-generating, given the limited statistical power of the trial. Adherence to dual antiplatelet therapy (DAPT) at 6 and 9 months and annually through 5 years for each study arm. Abbreviations as in Figure 2 . Values are n (%).
E-ZES ϭ Endeavor zotarolimus-eluting stent; PES ϭ Taxus paclitaxel-eluting stent.
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